Quantitative risk reduction through peanut immunotherapy: Assessment for the peanut-allergic population undergoing epicutaneous immunotherapy (EPIT)

被引：0
|
作者：
Remington, B. C. [1 ]
Krone, T. [1 ]
Koppelman, S. J. [2 ]
机构：
[1] TNO, Zeist, Netherlands
[2] Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE USA
来源：
ALLERGY | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
0111
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [41] Oral Immunotherapy (OIT) Induces Clinical Tolerance in Peanut-Allergic Children
    Varshney, P.
    Jones, S. M.
    Pons, L.
    Kulis, M.
    Steele, P. H.
    Kemper, A. R.
    Scurlock, A. M.
    Perry, T. T.
    Burks, A. W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S174 - S174
  • [42] Sublingual versus oral immunotherapy for peanut-allergic children: A retrospective comparison
    Kim, Edwin H.
    Varshney, Pooja
    Steele, Pamela
    Kamilaris, Janet
    Hiegel, Anne M.
    Carlisle, Suzanna K.
    Smith, P. Brian
    Scurlock, Amy M.
    Jones, Stacie M.
    Burks, A. Wesley
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 132 (02) : 476 - 478
  • [43] Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children
    Kim, Edwin H.
    Keet, Corinne A.
    Virkud, Yamini V.
    Chin, Stacy
    Ye, Ping
    Penumarti, Anusha
    Smeekens, Johanna
    Guo, Rishu
    Yue, Xiaohong
    Li, Quefeng
    Kosorok, Michael R.
    Kulis, Michael D.
    Burks, Wesley
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (06) : 1558 - +
  • [44] Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children
    Thyagarajan, A.
    Jones, S. M.
    Calatroni, A.
    Pons, L.
    Kulis, M.
    Woo, C. S.
    Kamalakannan, M.
    Vickery, B. P.
    Scurlock, A. M.
    Burks, A. Wesley
    Shreffler, W. G.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2012, 42 (08): : 1197 - 1205
  • [45] Safety and tolerability of subcutaneous immunotherapy (SCIT) with a modified peanut extract in peanut-allergic adults, adolescents and children
    Kim, E. H.
    Sicherer, S. H.
    Wood, R. A.
    Bindslev-Jensen, C.
    Hamilton, R. G.
    Shamji, M. H.
    Van Twuijver, E.
    Opstelten, D. J.
    De Kam, P. J.
    ALLERGY, 2017, 72 : 738 - 739
  • [46] Shared Cooking Equipment in Restaurants: A Quantitative Risk Assessment for Peanut-Allergic Consumers
    Remington, Benjamin C.
    Koppelman, Stef J.
    Bassa, Boris
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB239 - AB239
  • [47] QUANTITATIVE RISK REDUCTION THROUGH PEANUT IMMUNOTHERAPY: SAFETY BENEFITS OF AN INCREASED THRESHOLD IN EUROPE
    Remington, B.
    Krone, T.
    Koppelman, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S79 - S79
  • [48] Quantitative risk reduction through peanut immunotherapy: Safety benefits of an increased threshold in Europe
    Remington, Benjamin C.
    Krone, Tanja
    Koppelman, Stef J.
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2018, 29 (07) : 762 - 772
  • [49] Reduction in Severity Following 12 Months of Epicutaneous Immunotherapy for Peanut Allergy
    Begin, Philippe
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB108 - AB108
  • [50] Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in PEPITES and PEOPLE Studies
    DunnGalvin, A.
    Fleischer, D. M.
    Campbell, D. E.
    PEDIATRICS, 2021, 148 : S34 - S34
12345